CCR2 receptor antagonists and uses thereof
The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD.
1. A method for treating a neurologic disease selected from inflammatory and neuropathic pain, comprising administering to a patient in need thereof an effective amount of a pharmaceutical formulation containing a compound of Formula I, to treat the neurologic disease, wherein Formula I is
or a salt thereof.
2. The method of claim 1 , wherein the neurologic disease is inflammatory pain.
3. The method of claim 1 , wherein the neurologic disease is neuropathic pain.
4. The method of claim 3 , wherein the neuropathic pain is low back pain.
5. The method of claim 3 , wherein the neuropathic pain is trigeminal neuralgia.
6. The method of claim 3 , wherein the neuropathic pain is hip pain, leg pain, non-herpetic neuralgia, post herpetic neuralgia, diabetic neuropathy, nerve injury-induced pain, phantom limb pain, post-surgical pain, or stump pain.
7. The method of claim 1 , wherein the neurologic disease is neuropathic pain due to chemotherapy caused nerve injury.
8. The method of claim 2 , wherein the pharmaceutical formulation is administered orally to the patient.
9. The method of claim 3 , wherein the pharmaceutical formulation is administered orally to the patient.
10. The method of claim 4 , wherein the pharmaceutical formulation is administered orally to the patient.
11. The method of claim 5 , wherein the pharmaceutical formulation is administered orally to the patient.
12. A method for treating a neurologic disease selected from inflammatory and neuropathic pain, comprising administering to a patient in need thereof an effective amount of pharmaceutical formulation containing a compound of Formula I, to treat the neurologic disease, wherein Formula I is an acid addition salt formed by a pharmacologically acceptable acid and the following compound:
13. The method of claim 12 , wherein the neurologic disease is inflammatory pain.
14. The method of claim 12 , wherein the neurologic disease is neuropathic pain.
15. The method of claim 14 , wherein the neuropathic pain is low back pain.
16. The method of claim 14 , wherein the neuropathic pain is trigeminal neuralgia.
17. The method of claim 14 , wherein the neuropathic pain is hip pain, leg pain, non-herpetic neuralgia, post herpetic neuralgia, diabetic neuropathy, nerve injury-induced pain, phantom limb pain, post-surgical pain, or stump pain.
18. The method of claim 12 , wherein the neurologic disease is neuropathic pain due to chemotherapy caused nerve injury.
19. The method of claim 13 , wherein the pharmaceutical formulation is administered orally to the patient.
20. The method of claim 14 , wherein the pharmaceutical formulation is administered orally to the patient.
21. The method of claim 15 , wherein the pharmaceutical formulation is administered orally to the patient.
22. The method of claim 16 , wherein the pharmaceutical formulation is administered orally to the patient.
23. The method of claim 3 , wherein the neuropathic pain is leg pain.
24. The method of claim 3 , wherein the neuropathic pain is nerve injury-induced pain.
25. The method of claim 14 , wherein the neuropathic pain is leg pain.
26. The method of claim 14 , wherein the neuropathic pain is nerve injury-induced pain.